Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Merck & Co. has bought into the kind of drug that has emerged as a top threat to its dominant cancer immunotherapy Keytruda. The company said Thursday it agreed to pay privately-held LaNova ...

The cancer immunotherapy Keytruda, Merck’s most important product and the best-selling drug in the world with $23 billion in annual sales, is set to lose patent protection and face competition ...

Vibostolimab/Keytruda regimen did not improve overall survival compared to Tecentriq in extensive-stage SCLC patients. Median ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

high risk early stage TNBC before surgery. After surgery, Keytruda is continued as a treatment by itself, without chemotherapy. Colon cancer and other solid tumors: Keytruda is used for colon ...

Keytruda, a drug for different cancer indications, generates by far the most revenue, more than half of the company’s total revenue. And those sales keep on increasing year-over-year.

Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug Keytruda in certain patients with a ...

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose ...

KEYTRUDA plus chemotherapy is the first approval ... for patients with FIGO 2014 Stage III-IVA locally advanced cervical cancer "These KEYTRUDA-based regimens have the potential to change the ...

Keytruda (pembrolizumab) is a brand-name solution for IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects ...

In KEYNOTE-A18, KEYTRUDA in combination with concurrent CRT demonstrated statistically significant and clinically meaningful improvements in overall survival (OS) and PFS compared to concurrent CRT ...